Deverra Therapeutics Granted FDA Fast Track Designation for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemia

April 24, 2024 4:30 PM

SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic universal donor cell therapy treatments to fight cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track (FT) designation to dilanubicel, the Company's lead candidate for the treatment of newly diagnosed acute myeloid leukemia (AML) to improve...

Read more

BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024

April 24, 2024 10:20 AM

The two poster presentations will report -first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy armcombination data from the Phase 1/2a study with BI-1206 in combination with KEYTRUDA for the treatment of patients with solid tumorsBoth BI-1808 and BI-1206 are first-in-class immunomodulatory agents with the potential to improve the...

Read more

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium

April 24, 2024 6:15 AM

Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Patients at the Two-Year Milestone8.08 Points for Patients at the One-Year Milestone8.71 Points for Patients at the Six-Month Milestone72% of the Study Patients Showing Clinical Meaningful Benefit from the VenoValve at a Weighted Average of 11 Months...

Read more

BioInvent International AB: Interim Report January-March 2024

April 24, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV)"During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahead in 2024, we are preparing for multiple data presentations for our six ongoing clinical programs." - Martin Welschof, CEO of BioInvent.EVENTS IN THE FIRST...

Read more

Biovica Saves SEK 30 Million/Year and Investigates New Go-To Market Model in US

April 23, 2024 10:15 AM

UPPSALA, SE / ACCESSWIRE / April 23, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, announces a cost reduction program in Sweden and the US that will result in annual cost savings of approximately SEK 30 million and a restructuring cost of SEK 8 million. At the same time, Biovica is investigating the opportunity to change its go-to-market model in the US from having its own...

Read more

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health

April 23, 2024 9:15 AM

Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patients(Please see important safety information below)NEW YORK, NY / ACCESSWIRE / April 23, 2024 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces a new collaboration with Lemonaid Health, leading...

Read more

Enzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in Nevada

April 23, 2024 8:30 AM

Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com)(the "Company") today disclosed that on April 9, 2024, the US District Court of Nevada dismissed the lawsuit, 22-cv-00401-GMN-DJA brought by Dimitar Savov against IMMB bringing to an end the claims alleged in this suit. Originally filed on March 3, 2022 against the corporation that ENZC had its assets, including ITV-1, IMMB and ENZC have successfully defended their position against the plaintiff...

Read more

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

April 23, 2024 7:31 AM

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announced today an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The technology was...

Read more

Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results

April 22, 2024 9:00 AM

VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TM Platform. LENSai, which is run by the company's subsidiary, BioStrand, provides a unique and comprehensive view of life sciences data by linking sequence, structure, function and literature information from the entire...

Read more

Intellistem, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

April 22, 2024 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / April 22, 2024 / Intellistem, Inc, (private), is the developer of an innovative Cell Therapy that has shown reduced or eliminated tumors in 30 patients, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 10:30AM (Local Time -PST). Bill St John, CEO of Intellistem Inc. will be hosting the presentation and answering questions at the conclusion.To...

Read more

Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split

April 19, 2024 12:10 PM

BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the Company's...

Read more

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

April 19, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / April 19, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the Company's webcast presentation and discussion during the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 17, 2024 is...

Read more

Form Bio Establishes Scientific Advisory Board, Comprised of Renowned Experts in Cell and Gene Therapy, for Advancing AI-Driven Therapies

April 18, 2024 8:00 AM

Bringing Together the Top Minds Across Vector Engineering, Viral Vector Delivery Systems and Next-Generation Gene Transfer Technologies Further Cements Form Bio's Position as a Leader in AI-Driven Cell and Gene TherapyDALLAS, TX / ACCESSWIRE / April 18, 2024 / Form Bio, the breakthrough computational life sciences solutions provider, today announced the creation of a new Scientific Advisory Board (SAB). This esteemed board will provide strategic...

Read more

Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)

April 16, 2024 9:15 AM

(Please see important safety information below)NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has received positive feedback from the U.S. Food and Drug Administration (the "FDA," or the "Agency") following the FDA's informal review of Petros'...

Read more

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

April 16, 2024 9:00 AM

IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that additional topline efficacy data from the VenoValve U.S. pivotal trial will be presented at the 2024 Charing Cross International Symposium being held April 23rd - 25th in London, England. The presentation, entitled "Efficacy Results of...

Read more

Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run

April 16, 2024 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, announces that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial."Taking the time to...

Read more

AmplifyBio and RNAV8 Bio Announce Strategic Partnership to Support mRNA Therapeutic Developers from Sequence Design to GMP Manufacture

April 16, 2024 7:00 AM

NEW ALBANY, OH / ACCESSWIRE / April 16, 2024 / AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services that cover target optimization, preclinical safety studies, and manufacturing scale-up, and RNAV8 Bio, an emerging startup focused on mRNA engineering platforms, are partnering to provide a one-stop shop for the development of mRNA therapeutics. The...

Read more

Biolog Expands the Odin Family, and Access to Cellular Characterization, With the Launch of Odin VIII

April 16, 2024 7:00 AM

HAYWARD, CA / ACCESSWIRE / April 16, 2024 / Biolog, Inc., a leading provider of cell-based microbial identification and phenotypic and metabolic profiling products and services, today announced the launch of OdinTM VIII system, the newest member of its Odin family of instruments. Designed to meet the needs of laboratories with mid-throughput requirements, Odin VIII is a smaller yet equally powerful version of the Odin platform introduced last...

Read more

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

April 15, 2024 8:31 AM

Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovationBRIDGEWATER, NJ / ACCESSWIRE / April 15, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced today the formation of a new Scientific Advisory...

Read more

Ondine Biomedical Inc. Announces 32% Fewer SSIs After Steriwave Replaced Mupirocin

April 15, 2024 2:00 AM

New data shows reduced cardiac infections and significant cost savings after the light-activated antimicrobial, Steriwave, replaced the antibiotic standard of care at the Mazankowski Alberta Heart InstituteVANCOUVER, BC / ACCESSWIRE / April 15, 2024 / Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that an independent study undertaken at the world renowned...

Read more